Myosotis Therapeutics AG is developing medication helping to delay or prevent Alzheimer’s disease. Our approach is based on research conducted in two of Europe’s leading academic institutions, Universität Zürich and Charité - Universitätsmedizin Berlin, and published in high-ranking research journals such as Nature Medicine.
To date, no drug has been proven to modify the processes causing memory loss and cognitive impairment in patients suffering from dementia. Myosotis’ approach targets p40, a component of the immune system, which has been shown to be overly present in patients suffering from Alzheimer’s disease (AD).
Blocking p40 has had significant success in animal models of AD both reducing the plaques typically seen in the disease, and improving cognitive function. These findings need to be confirmed in clinical trials and Myosotis was founded for this purpose.
We do not know yet whether this therapy will be effective, and whilst we are optimistic based on our understanding of the underlying science, we do not want to raise hope that a cure for this terrible disease is available in the short term. We will post the results of all of our clinical trials on this site, and provide regular updates on our progress. In the meantime, anyone looking for support for AD patients is encouraged to browse the links on the patients’ page.